Selective suppression of chemokine receptor CXCR3 expression by interferon-b1a in multiple sclerosis

Abstract

We studied the expression of chemokine receptors CCR1, CCR2, CCR3, CCR5, and CXCR3 on CD4 and CD8 positive T cells, and on CD14 positive monocytes in blood from 10 patients with relapsing-remitting multiple sclerosis (MS) at initiation of interferon (IFN)- βtreatment, after 1 month and after 3 months of treatment. It was found that the expression of CXCR3 on CD4+ and CD8+ T cells was significantly reduced after 3 months of treatment. The expression of other receptors was unaltered. Since CXCR3 cells are enriched in cerebrospinal fluid (CSF), and are detected in lesion material in MS this may represent an important mode of action of interferon- βin MS.

Keywords

chemokine receptors chemokines demyelinating disease multiple sclerosis neuroimmunology

Get full access to this article

View all access options for this article.

References

Noseworthy JR. Progress in determining the causes and treatment of multiple sclerosis . Nature 1999; 399: A40-A47 .

Yong VW , Chabot S , Stuve O , Williams G. Interferon beta in the treatment of multiple sclerosis: mechanismsof action . Neurology 1998; 51: 682-689 .

Rudick RA , Cookfair DL , Simonian NA , Ransonoff RM , Richert JR , Jacons LD , et al. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis . J Neuroimmunol 1999; 93: 8-14 .

Baggiolini M. Chemokines and leukocyte traffic . Nature 1998; 392: 565-568 .

Sørensen TL , Tani M , Jensen J , Pierce V , Lucchinetti C , Folcik VA , et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients . J Clin Invest 1999; 103: 807-815 .

Balashov KE , Rottman JB , Weiner HL , Hancock WW. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1alfa and IP-10 are expressed in demyelinating brain lesions . Proc Natl Acad Sci USA 1999; 96: 6873-6878 .

Iarlori C , Reale M , Lugaresi A , De Luca U , Bonanni L , Di Forio A , et al. RANTES production and expression is reduced in relapsing remitting multiple sclerosis patients treated with interferon beta-1b . J Neuroimmunol 2000; 107: 100-107 .

Stuve O , Chabot S , Jung SS , Williams G , Yong VW. Chemokine-enhanced migration of human peripheral blood mononu-clear cells is antagonized by interferon beta-1b through an effect on matrix metalloproteinase-9 . J Neuroimmunol 1997; 80: 38-46 .

Strunk T , Bubel S , Mascher B , Schlenke P , Kirschner H , Wandinger ICP. Increased number of CCR5+ interferon-gamma- and tumor necrosis factor-alpha secreting T lymphocytes in multiple sclerosis patients . Ann Neurol 2000; 47: 267-273 .

10.

Sellebjerg F , Madsen HO , Jensen CV , Jensen J , Garred P. CCR5D32, matrix metalloproteinase-9 and disease activity in multiple sclerosis . J Neuroimmunol 2000; 102: 98-106 .

11.

Calabresi PA , Stone LA , Basch CN , Frank JA , McFarland HF. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI . Neurology 1997; 48: 1446-1448 .

12.

Zang YC , Halder JB , Samanta AK , Hong J , Rivera VM , Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta . J Neuroimmunol 2001; 112: 174-180 .

13.

Balashov KE , Olek MJ , Smith DR , Khoury SJ , Weiner HL. Seasonal variation of interferon-gamma production in progressive multiple sclerosis . Ann Neurol 1998; 44: 824-828 .